In addition, the tumor-initiating ability of residual tumor cells and the proportion of CSCs found in tumor xenografts at the end of Folfiri treatment were strongly decreased in PXR knockdowns (Figure 6). The gene discussed is NR1I2; the disease is neoplasm.